Acute myeloid leukemia, often called AML, is one of the most aggressive forms of blood cancer. It develops in the bone marrow, the soft tissue inside bones where blood cells are made.
In healthy people, the bone marrow produces red blood cells that carry oxygen, white blood cells that fight infection, and platelets that help stop bleeding.
In AML, this process goes wrong. The bone marrow begins producing large numbers of abnormal white blood cells that do not work properly. These cancer cells grow very quickly and crowd out the healthy blood cells the body needs to function.
Because AML grows so fast, it usually requires immediate and intensive treatment. Doctors typically begin treatment with strong chemotherapy to destroy as many cancer cells as possible.
When the treatment works well, the cancer becomes undetectable in blood tests and the patient’s blood counts return to normal. This stage is called remission. However, remission does not always mean the disease is cured. In many patients, the leukemia returns after some time.
For many people with AML, the only chance for a long‑term cure is a stem cell transplant. In this procedure, doctors replace the patient’s diseased bone marrow with healthy blood‑forming stem cells from a donor. These new cells can rebuild the patient’s blood system and help the body produce normal blood cells again.
However, a transplant can only be performed when the leukemia is first brought under control with chemotherapy. If the disease continues to grow or returns after treatment, it becomes much harder to prepare patients for a successful transplant.
A new study led by researchers at Dresden University Medicine in Germany has found a promising way to improve the chances of remission in people whose leukemia has returned or stopped responding to standard treatment.
The research team investigated whether combining traditional chemotherapy with a newer targeted drug called venetoclax could improve treatment outcomes.
The study was carried out across several medical centers in Germany and was known as the RELAX study. The results were published in the medical journal The Lancet Haematology, which is an international journal focused on blood diseases and cancer research.
The research was led by Professor Christoph Röllig from the University Hospital Dresden, together with his colleague Dr. Leo Ruhnke and other specialists in blood cancers. The team wanted to find out whether adding venetoclax to an established chemotherapy treatment could help more patients reach remission.
The chemotherapy used in the study included two well‑known drugs called cytarabine and mitoxantrone. This combination is often referred to as the HAM regimen. These drugs attack rapidly growing cancer cells and are commonly used to treat AML.
However, when AML returns after earlier treatment, standard chemotherapy alone often fails to fully control the disease.
Venetoclax works in a different way from chemotherapy. It targets a protein called BCL‑2 that helps cancer cells survive. By blocking this protein, venetoclax makes leukemia cells more likely to die. Scientists hoped that combining this targeted drug with chemotherapy would make treatment more powerful.
The RELAX study was designed as an early phase clinical trial, which means the researchers first examined whether the treatment was safe and tolerable for patients. After confirming that patients could handle the therapy, the team studied how effective the treatment was at controlling leukemia.
The results were encouraging. In earlier treatments for patients whose AML had returned, only about 40 percent of patients achieved complete remission. In contrast, when patients received the combination of HAM chemotherapy and venetoclax, remission was achieved in about 75 percent of cases.
This improvement is important because reaching remission allows many more patients to move forward to stem cell transplantation. According to the researchers, most of the patients who responded to the new treatment were able to receive a transplant afterward, which offers the best chance for long‑term survival.
The scientists also observed that the treatment appeared to work even in patients with particularly difficult forms of AML caused by certain genetic changes. These forms of leukemia are often resistant to treatment, so the ability to control them more effectively is a promising development.
Professor Martin Bornhäuser, another researcher involved in the study and director at the Medical Clinic I in Dresden, said the results suggest a much more hopeful outlook for patients treated with the new combination therapy. He explained that cooperation between academic researchers and industry partners helped make this progress possible.
After the RELAX study finished recruiting participants, doctors in Germany continued using the treatment approach. Researchers are now analyzing results from more than 150 additional patients who received the same therapy outside the original study.
Early results from these cases also appear promising, suggesting that the treatment could become widely used in the future.
Experts believe the HAM‑venetoclax combination could eventually become a new standard treatment for patients whose AML has returned or stopped responding to earlier therapy. By helping more patients reach remission, the treatment may serve as an important bridge that allows them to receive life‑saving stem cell transplants.
This study is important because it highlights how combining traditional cancer treatments with newer targeted medicines can significantly improve results. Instead of relying only on chemotherapy, doctors are increasingly using therapies that attack specific weaknesses in cancer cells.
However, the findings should still be viewed carefully. The RELAX study was an early‑phase clinical trial, which means larger studies will be needed to confirm the benefits and safety of the treatment in a wider group of patients. Cancer treatments must be tested carefully before they become standard practice.
Even so, the results represent a meaningful step forward in the fight against acute myeloid leukemia. For patients whose disease has returned and who have limited treatment options, the combination of chemotherapy and venetoclax may offer a much better chance of reaching remission and receiving a potentially curative stem cell transplant.
In reviewing the study, the findings appear strong because the improvement in remission rates is large and clinically meaningful. Increasing remission from 40 percent to 75 percent could translate into many more patients being eligible for life‑saving transplants.
The study also highlights the value of targeted drugs that weaken cancer cells and make chemotherapy more effective. If future larger trials confirm these results, the therapy could change how doctors treat relapsed AML and improve survival for many patients.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and berry that can prevent cancer, diabetes, and obesity.
For more health information, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing vitamin D supplements could strongly reduce cancer death.
Copyright © 2026 Knowridge Science Report. All rights reserved.
